Skip to content
AnalystLens

Leidos Holdings Quarterly Report for Q1 Ended Mar 31, 2023

Filing Date
Filed May 2, 2023
Period End
March 31, 2023
Security
LDOS
One revenue dollarkept$0.04
In the record · 2016–202610-K1210-Q338-K130

LDOS filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 130 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Aug ’17Aug ’17
  2. Leadership change8-K · Mar ’20Mar ’20
  3. Leadership change8-K · Feb ’22Feb ’22
  4. Material agreement8-K · Oct ’26Oct ’26

Summary

Summary of the 10-Q filed May 2, 2023. Cited figures are marked; the original filing is the authoritative source.

Leidos Holdings, Inc. reported revenues of $3.70 billiona for the three months ended March 31, 2023, up from $3.49 billion in the prior-year quarter.

Operating income was $265 millionb compared with $271 million, and net income attributable to Leidos common stockholders was $162 million versus $175 million. Diluted earnings per share were $1.17, compared with $1.25. The filing attributes the revenue increase to program wins, higher volumes on certain programs and the Cobham Special Mission acquisition, partly offset by contract completions.

Operating margin was 7.2%, compared with 7.8% a year earlier. Net bookings were an estimated $3.0 billionc, down from $5.4 billion, and total backlog was $35.1 billion, including $610 million acquired through a business combination. Cash flow and liquidity shifted during the quarter.

Net cash used in operating activities was $98 milliond, compared with $93 million of cash provided in the prior-year quarter, which the company primarily attributed to higher tax payments of $127 million tied to a Tax Cuts and Jobs Act provision and a $62 million payment for payroll taxes related to the CARES Act. The company refinanced its debt in the quarter, issuing $750 million of 5.75% senior notes due 2033 and entering a Credit Agreement with a $1.0 billion term loan and a $1.0 billion revolving facility, both maturing in March 2028. Total debt was $5.0 billion at March 31, 2023, and cash and cash equivalents were $379 million.

Management stated it expects to meet liquidity needs for the next 12 months and anticipates tax cash payments to increase by $300 million in 2023. The filing also discloses ongoing government matters. The company self-reported to the Department of Justice and the SEC an internal investigation into international operations that may have violated the U.S. Foreign Corrupt Practices Act, and it received a grand jury subpoena from the Department of Justice Antitrust Division in August 2022.

The company stated it cannot predict the timing or outcome of these matters. In the VirnetX matter, the Federal Circuit on March 31, 2023 vacated the District Court's judgment in the Apple II case and remanded it with instructions to dismiss as moot, and the filing states no assurances can be given that Leidos will receive any proceeds.

Key Highlights

  1. Revenues rose to $3.70 billion from $3.49 billion, driven by program wins, higher volumes and the Cobham Special Mission acquisition.
  2. Operating income declined to $265 million from $271 million, with operating margin of 7.2% versus 7.8%.
  3. Diluted EPS was $1.17 versus $1.25, and net income attributable to Leidos common stockholders was $162 million versus $175 million.
  4. Operating cash flow was negative $98 million, reflecting $127 million of higher tax payments tied to the TCJA research and development provision.
  5. Total backlog was $35.1 billion and remaining performance obligations were $14.5 billion, while net bookings fell to $3.0 billion from $5.4 billion.
  6. The company refinanced its debt, issuing $750 million of 5.75% notes due 2033 and entering a $1.0 billion term loan and $1.0 billion revolving credit facility maturing March 2028; total debt was $5.0 billion.
  7. Ongoing DOJ and SEC investigations related to FCPA compliance and a DOJ Antitrust Division subpoena remain open, with the company stating it cannot predict their outcome.

Follow one dollar

Of each $1.00 of revenue in Q1 FY2024, Leidos Holdings kept $0.04.

  1. Revenue$3.68B100.0%
  2. Cost of revenue−$3.20B87.1%
  3. Gross profit$475.0M12.9%
  4. Operating costs−$210.0M5.7%
  5. Operating income$265.0M7.2%
  6. Interest, other & tax−$103.0M2.8%
  7. Net income$162.0M4.4%
Computed from 10-QQ1 FY2024filed May 2, 2023Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Financial Statements

Q1 FY2024 against Q1 FY2023

Line itemQ1 FY2024Q1 FY2023Change
Revenue$3.68B$3.48B+5.8%
Cost of Revenue$3.20B$2.98B+7.4%
Gross Profit$475.00M$496.00M−4.2%
SG&A Expenses$233.00M$236.00M−1.3%
Operating Income$265.00M$271.00M−2.2%
Net Income$162.00M$175.00M−7.4%
EPS (Basic)$1.18$1.26−6.3%
EPS (Diluted)$1.17$1.25−6.4%
Shares Outstanding (Basic)137.00M139.00M−1.4%
Shares Outstanding (Diluted)138.00M140.00M−1.4%

Frequently Asked Questions

  1. What drove the change in revenue and operating income this quarter?

    Revenues increased to $3,699 million from $3,494 million. The filing attributes the increase to program wins, a net increase in volumes on certain programs and a $30 million contribution from the Cobham Special Mission acquisition, partly offset by completion of certain contracts. Operating income fell to $265 million from $271 million; Defense Solutions operating income rose to $147 million, while Civil fell to $40 million and Health fell to $107 million, with Corporate costs at $29 million.

  2. Why was operating cash flow negative this quarter?

    Net cash used in operating activities was $98 million, compared with $93 million provided in the prior-year quarter. The company primarily cited higher tax payments of $127 million, largely connected to the TCJA provision that requires capitalizing research and development costs, and a $62 million payment for payroll taxes related to the CARES Act. The company anticipates tax cash payments will increase by $300 million in 2023.

  3. How did the company change its debt structure this quarter?

    In February 2023 the company issued $750 million of 5.75% senior notes due March 2033, and on March 10, 2023 it entered a Credit Agreement providing a $1.0 billion senior unsecured term loan and a $1.0 billion revolving facility, both maturing in March 2028. Proceeds and cash on hand were used to repay the $1.9 billion term loan facility and the $750 million revolving facility, and the $500 million 2.95% notes due May 2023 were largely retired. Total debt was $5.0 billion at March 31, 2023, with $379 million of cash and cash equivalents.

  4. What are the main legal and regulatory risks disclosed?

    The company disclosed an internal investigation, overseen by an independent Board committee, into conduct by employees, third-party representatives and subcontractors in part of its international operations, which may have violated the U.S. Foreign Corrupt Practices Act. It self-reported the matter to the DOJ and SEC, received a Federal Grand Jury subpoena in September 2022, and a former employee was indicted in February 2023. The company also received an August 2022 DOJ Antitrust Division subpoena concerning three U.S. Government procurements. The filing states the company cannot anticipate the timing, outcome or possible impact of these investigations.

  5. What happened with the VirnetX patent litigation?

    Under agreements with VirnetX, Leidos would receive 25% of proceeds obtained by VirnetX after attorneys' fees and costs. On March 30, 2023, the Federal Circuit affirmed USPTO Patent Trial and Appeal Board decisions finding certain claims unpatentable, and on March 31, 2023, it vacated the District Court's judgment in the Apple II case and remanded with instructions to dismiss as moot. The filing states that no assurances can be given when or if Leidos will receive any proceeds, and that any proceeds would require a royalty payment to the customer who funded the technology's development.